Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 3/20 | 0.56 |
| ▸ | NOS1 | P29475 | 3/20 | 0.56 |
| ▸ | NOS2 | P35228 | 3/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.39 |
| ▸ | FYN | P06241 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 2/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29492793 | 1.00 | NOS3 (0.56) | NOS3NOS1NOS2MAP4K4FGFR1 | |
| SCHEMBL2957518 | 0.80 | ALDH1A1 (0.42) | NOS3NOS1NOS2MAP4K4FGFR1 | |
| SCHEMBL2901554 | 0.78 | FYN (0.45) | NOS3NOS1NOS2FYNALDH1A1 | |
| SCHEMBL24738147 | 0.78 | HTT (0.56) | NOS3NOS1NOS2MAP4K4FGFR1 | |
| SCHEMBL7940187 | 0.77 | ALDH1A1 (0.39) | NOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL28790793 | 0.77 | FYN (0.48) | NOS3NOS1NOS2FYNALDH1A1 | |
| SCHEMBL12563479 | 0.77 | TAAR1 (0.42) | NOS3NOS1NOS2MAP4K4FGFR1 | |
| SCHEMBL22207152 | 0.77 | NOS3 (0.39) | NOS3NOS1NOS2FGFR1FYN | |
| SCHEMBL13180941 | 0.77 | NOS3 (0.39) | NOS3NOS1NOS2MAP4K4FGFR1 | |
| SCHEMBL16416335 | 0.76 | NOS3 (0.44) | NOS3NOS1NOS2MAP4K4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110128422-B | Synthesis method of 5-methoxy-7-azaindole | 金凯(辽宁)生命科技股份有限公司 | 2022-03-18 | — | — | CN | claimed |
| CN-110128422-A | The synthetic method of 5- methoxyl group -7- azaindole | 金凯(辽宁)化工有限公司 | 2019-08-16 | — | — | CN | claimed |
| US-20230365559-A1 | NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER | AUCKLAND UNISERVICES LIMITED (NZ) | 2023-11-16 | — | — | US | disclosed |
| CN-116669725-A | Novel aminopyridine and use thereof in the treatment of cancer | 奥克兰联合服务有限公司 | 2023-08-29 | — | — | CN | disclosed |
| EP-4217357-A1 | NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER | Auckland Uniservices Limited (NZ) | 2023-08-02 | — | — | EP | disclosed |
| EP-4137491-A1 | IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE | Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) | 2023-02-22 | — | — | EP | disclosed |
| WO-2022064430-A1 | NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER | AUCKLAND UNISERVICES LIMITED (NZ) | 2022-03-31 | — | — | WO | disclosed |
| CN-110128422-B | Synthesis method of 5-methoxy-7-azaindole | 金凯(辽宁)生命科技股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2021209055-A1 | IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE | 成都百裕制药股份有限公司 | 2021-10-21 | — | — | WO | disclosed |
| CN-110128422-A | The synthetic method of 5- methoxyl group -7- azaindole | 金凯(辽宁)化工有限公司 | 2019-08-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365559-A1 | NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER | DCK, DTYMK, TYMP | NOS3 2125/4885NOS1 1871/4885NOS2 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.